Gilead Sciences (GILD) Stock Forecast & Price Target

$150.89 +3.21 (+2.17%)

Closing price 04:00 PM Eastern

Extended Trading

$150.62 -0.27 (-0.18%)

As of 07:12 PM Eastern

Compare

Gilead Sciences - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 29 Analyst Ratings

Sell
0

Hold
5

Buy
24

Based on 29 Wall Street analysts who have issued ratings for Gilead Sciences in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 29 analysts, 5 have given a hold rating, 23 have given a buy rating, and 1 has given a strong buy rating for GILD.

Consensus Price Target

$158.78
5.23% Upside

According to the 29 analysts' twelve-month price targets for Gilead Sciences, the average price target is $158.78. The highest price target for GILD is $180.00, while the lowest price target for GILD is $123.00. The average price target represents a forecasted upside of 5.23% from the current price of $150.89.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for GILD and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Gilead Sciences and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

GILD Analyst Ratings Over Time

Type	Current Forecast 9/17/25 to 9/17/26	1 Month Ago 8/18/25 to 8/18/26	3 Months Ago 6/19/25 to 6/19/26	1 Year Ago 9/17/24 to 9/17/25
Strong Buy	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	23 Buy rating(s)	24 Buy rating(s)	25 Buy rating(s)	19 Buy rating(s)
Hold	5 Hold rating(s)	5 Hold rating(s)	4 Hold rating(s)	6 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$158.78	$158.04	$158.41	$117.17
Forecasted Upside	5.23% Upside	10.18% Upside	28.00% Upside	4.37% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

GILD Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

GILD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Gilead Sciences Stock vs. The Competition

Type	Gilead Sciences	Healthcare Companies	Broader Market
Consensus Rating Score	2.86	2.30	2.53
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	7.51% Upside	752.92% Upside	18.17% Upside
News Sentiment Rating	Positive News See Recent GILD News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
9/14/2026	Weiss Ratings 5 of 5 stars		Upgrade	Hold (C-) ➝ Hold (C)
9/10/2026	HSBC 3 of 5 stars	Morten Herholdt Not Rated	Boost Target	Buy	$155.00 ➝ $175.00	+20.61%
8/31/2026	Zacks Research 5 of 5 stars		Upgrade	Hold ➝ Strong-Buy
8/5/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brian Abrahams Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Sector Perform	$120.00 ➝ $123.00	-5.89%
8/5/2026	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Carter Gould Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight	$155.00	+14.60%
8/5/2026	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joseph Stringer Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$170.00	+25.69%
7/29/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Emily Field Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Equal Weight	$155.00 ➝ $145.00	+7.95%
7/27/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matthew Harrison Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$166.00 ➝ $165.00	+25.39%
7/21/2026	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Daina Graybosch Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$146.00 ➝ $127.00	-4.66%
7/7/2026	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Gregory Renza Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$157.00 ➝ $156.00	+20.36%
My top 3 AI picks for the next decade (Ad) Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade. Click here to get all three AI stock names from Alexander Green
5/20/2026	Maxim Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Okunewitch Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Hold ➝ Buy	$165.00	+26.44%
5/19/2026	Daiwa Securities Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Outperform	$161.00 ➝ $150.00	+14.65%
5/11/2026	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target		$170.00 ➝ $167.00	+25.18%
4/17/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Neutral	$125.00 ➝ $130.00	-5.41%
4/13/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Geoff Meacham Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$156.00 ➝ $165.00	+19.83%
3/10/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Akash Tewari Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Buy	$180.00	+22.76%
2/19/2026	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Buy	$135.00 ➝ $165.00	+9.18%
2/18/2026	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Outperform	$140.00 ➝ $170.00	+11.30%
2/12/2026	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Alexandria Hammond Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$155.00 ➝ $170.00	+9.11%
2/11/2026	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Courtney Breen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform	$160.00	+3.14%
2/11/2026	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target	Buy	$162.00	+4.03%
2/11/2026	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Outperform	$128.00 ➝ $165.00	+5.91%
2/11/2026	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Buy	$135.00 ➝ $155.00	-0.51%
2/11/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Tyler Van Buren Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$145.00 ➝ $160.00	+2.70%
2/11/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mohit Bansal Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$150.00 ➝ $165.00	+12.07%
2/11/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Chris Schott Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$150.00 ➝ $160.00	+8.67%
2/11/2026	Scotiabank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Louis Chen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Sector Outperform	$140.00 ➝ $177.00	+20.22%
1/26/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Yee Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$145.00 ➝ $155.00	+12.54%
1/26/2026	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Evan David Seigerman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$135.00 ➝ $150.00	+10.35%
9/5/2025	Dbs Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Moderate Buy
2/13/2025	DZ Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold ➝ Buy	$108.00	+4.54%
2/12/2025	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joseph Catanzaro Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$105.00 ➝ $110.00	+6.33%
11/7/2024	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Neutral	$80.00 ➝ $95.00	-2.30%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 07:11 PM ET.

Should I Buy Gilead Sciences Stock? GILD Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, September 15, 2026. Please send any questions or comments about these Gilead Sciences pros and cons to contact@marketbeat.com.

Gilead Sciences
Bull Case

Here are some ways that investors could benefit from investing in Gilead Sciences, Inc.:

The launch of Yeztugo, Gilead's every-six-month HIV prevention option, has exceeded expectations, with the company projecting $1 billion in revenue for its first full year on the market. This strong performance is driving growth in the HIV pre-exposure prophylaxis market, which is expanding at a rate of 14% to 15%, and Gilead's total prevention portfolio has already exceeded $1 billion in quarterly sales, representing an annualized run rate of approximately $4 billion.
Gilead Sciences, Inc. is currently trading at $146.30, a level that reflects a significant recovery from its 52-week low of $108.46 and positions the stock near its 52-week high of $157.29. This price action, combined with a beta of 0.33, suggests the stock offers lower volatility relative to the broader market while still participating in the sector's upward momentum, making it an attractive option for investors seeking stability with growth potential.
The company has secured a favorable legal ruling from the U.S. Court of Appeals for the Fourth Circuit, which upholds a preliminary injunction blocking the import and sale of foreign-market Gilead-branded HIV medications in the United States. This legal victory protects Gilead's market share and revenue streams by preventing price erosion from lower-cost imported versions of its drugs, thereby safeguarding its competitive position in the HIV treatment market.
Gilead's oncology pipeline is advancing with the planned launch of anito-cel, a cell therapy for fourth-line and later multiple myeloma, which executives describe as potentially "best in disease." The company has fully enrolled a second-line-plus multiple myeloma study with data expected next year and estimates the fourth-line multiple myeloma market represents a $3.5 billion opportunity, providing a significant new growth driver beyond its core HIV franchise.
Analysts maintain a "Moderate Buy" consensus rating for Gilead Sciences, Inc. with a consensus price target of $158.037, which implies approximately 8% upside from the current stock price of $146.30. This positive outlook is supported by the company's robust portfolio, strong cash flow generation, and the expectation that it faces no major patent expirations until 2036, providing long-term revenue stability.

Gilead Sciences
Bear Case

Investors should be bearish about investing in Gilead Sciences, Inc. for these reasons:

Gilead Sciences, Inc. reported a negative earnings per share of ($6.75) for the quarter ended August 3, 2026, resulting in a negative price-to-earnings ratio of -54.79. This indicates that the company is currently unprofitable on a trailing basis, which may concern investors seeking consistent earnings growth and could limit the stock's appeal to value-oriented investors who prioritize positive earnings metrics.
CEO Daniel O'Day has engaged in a series of significant stock sales, including a recent sale of 15,000 shares at an average price of $148.64 on September 1, 2026, and a larger sale of 115,640 shares at $150.00 on February 5, 2026. While insider selling can be part of routine financial planning, the consistent pattern of sales by the CEO and other executives, such as CFO Andrew Dickinson and Johanna Mercier, may signal a lack of confidence in the stock's near-term upside or a desire to diversify personal holdings.
Bank of America Corp DE reduced its stake in Gilead Sciences, Inc. by 6.7% during the second quarter, selling 1,329,871 shares, while The Manufacturers Life Insurance Company also decreased its position by 11.9%. These moves by major institutional investors suggest a potential shift in sentiment among large holders, which could impact the stock's liquidity and price stability, particularly if other large institutions follow suit in reducing their exposure.
Gilead's debt-to-equity ratio stands at 2.03, indicating a relatively high level of leverage compared to its equity base. While the company has a current ratio of 1.27 and a quick ratio of 1.09, suggesting adequate short-term liquidity, the high debt load could limit its financial flexibility in the event of economic downturns or increased interest rates, potentially constraining its ability to invest in new R&D or acquire new assets without taking on additional debt.
The company's revenue guidance for fiscal year 2026 is $30.1 billion to $30.4 billion, which is slightly below the consensus estimate of $30.5 billion. This conservative guidance, combined with the negative EPS reported in the most recent quarter, may indicate that Gilead is facing challenges in meeting higher growth expectations, potentially leading to disappointment among investors who anticipated stronger top-line performance and profitability in the near term.

GILD Forecast - Frequently Asked Questions

According to the research reports of 29 Wall Street equities research analysts, the average twelve-month stock price forecast for Gilead Sciences is $158.78, with a high forecast of $180.00 and a low forecast of $123.00.

29 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last year. There are currently 5 hold ratings, 23 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" GILD shares.

According to analysts, Gilead Sciences's stock has a predicted upside of 5.23% based on their 12-month stock forecasts.

Over the previous 90 days, Gilead Sciences's stock had 3 upgrades and 2 downgrades by analysts.

Gilead Sciences has been rated by research analysts at Barclays, Cantor Fitzgerald, HSBC, Leerink Partners, Morgan Stanley, Needham & Company LLC, Royal Bank Of Canada, Truist Financial, Weiss Ratings, and Zacks Research in the past 90 days.

Analysts like Gilead Sciences more than other "healthcare" companies. The consensus rating for Gilead Sciences is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how GILD compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Gilead Sciences Recommendations

MarketBeat monitors more than a dozen sources for Gilead Sciences analyst ratings, with the most recent rating issued on 9/14/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Gilead Sciences (GILD) Stock Forecast & Price Target

Gilead Sciences - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

GILD Analyst Ratings Over Time

GILD Analyst Recommendations By Month

GILD Price Targets by Month

Gilead Sciences Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Gilead Sciences Stock? GILD Pros and Cons Explained

Gilead Sciences
Bull Case

Gilead Sciences
Bear Case

GILD Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Gilead Sciences Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Gilead Sciences (GILD) Stock Forecast & Price Target

Gilead Sciences - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

GILD Analyst Ratings Over Time

GILD Analyst Recommendations By Month

GILD Price Targets by Month

Gilead Sciences Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Gilead Sciences Stock? GILD Pros and Cons Explained

Gilead Sciences Bull Case

Gilead Sciences Bear Case

GILD Forecast - Frequently Asked Questions

What is Gilead Sciences' forecast for 2026?

Should I buy or sell Gilead Sciences stock right now?

Does Gilead Sciences's stock price have much upside?

Has Gilead Sciences been upgraded or downgraded by Wall Street analysts recently?

What analysts cover Gilead Sciences?

Do Wall Street analysts like Gilead Sciences more than its competitors?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Gilead Sciences Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

Gilead Sciences
Bull Case

Gilead Sciences
Bear Case